Panacea Life Sciences Holdings, Inc. (PLSH)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.52 Million | -2.39 Million | -3.92 Million | -7.64 Million | -5.74 Million | -465.75 Thousand |
| Net Income | -8.01 Million | -9.14 Million | -4.78 Million | -5.23 Million | -9.48 Million | -4.33 Million |
| Depreciation & Amortization | 1.71 Million | 1.73 Million | 965.09 Thousand | 344.59 Thousand | 892.29 Thousand | 405.17 Thousand |
| Deferred income taxes | - | - | - | -1.32 Million | -1.15 Million | - |
| Stock-based compensation | - | - | - | 1.32 Million | 3.77 Million | - |
| Change in working capital | 1.04 Million | 1.56 Million | 632.38 Thousand | -2.82 Million | -1.69 Million | 1.13 Million |
| Other non-cash items | 3.73 Million | 3.45 Million | -737.16 Thousand | 61.4 Thousand | 8.32 Million | 2.73 Million |
| Investing Cash Flow | -65.32 Thousand | -196.97 Thousand | 522.53 Thousand | -3.08 Million | -2.04 Million | - |
| Investments in PPE | -65.32 Thousand | -243.8 Thousand | -162.94 Thousand | -3.2 Million | -541.2 Thousand | - |
| Acquisitions | - | - | 9157.00 | 119.62 Thousand | -1.5 Million | - |
| Investment purchases | - | - | - | 3.08 Million | - | - |
| Sales/Maturities of investments | - | 46.83 Thousand | 446.02 Thousand | 119.62 Thousand | - | - |
| Other Investing Activities | -65.32 Thousand | 46.83 Thousand | 230.29 Thousand | -119.62 Thousand | 1.00 | - |
| Financing Cash Flow | 1.68 Million | 2.58 Million | 3.33 Million | 2.29 Million | 7.8 Million | 306.5 Thousand |
| Debt repayment | -1.39 Million | -1.76 Million | -210.55 Thousand | -3.96 Million | -716.05 Thousand | -256.5 Thousand |
| Dividends payments | - | - | - | - | -904.45 Thousand | - |
| Common Stock Repurchased | - | - | - | - | 1.44 Million | - |
| Common Stock Issuance | - | 55 Thousand | 4.36 Million | 385 Thousand | 7.21 Million | 50 Thousand |
| Other Financing Activities | 292.94 Thousand | 4.28 Million | -823.57 Thousand | 5.87 Million | -127.5 Thousand | 256.5 Thousand |
| Accounts receivables | 431.31 Thousand | 38.36 Thousand | -97.19 Thousand | 151.67 Thousand | -107.16 Thousand | - |
| Accounts payables | 1.98 Million | 1.08 Million | 1.06 Million | 684.57 Thousand | 973.49 Thousand | 188.37 Thousand |
| Inventory | 297.39 Thousand | -184.44 Thousand | -547.91 Thousand | -5.04 Million | -2.86 Million | - |
| Other working capital | 318.2 Thousand | 624 Thousand | 207.81 Thousand | 1.39 Million | 302.16 Thousand | 1.13 Million |
| Cash at beginning of period | 6951.00 | 19.77 Thousand | 84.37 Thousand | 8.51 Million | 1960.00 | 161.21 Thousand |
| Cash at end of period | 100.92 Thousand | 6951.00 | 19.77 Thousand | 84.37 Thousand | 18.4 Thousand | 1960.00 |
| Capital Expenditure | -65.32 Thousand | -243.8 Thousand | -162.94 Thousand | -3.2 Million | -541.2 Thousand | - |
| Effect of forex changes on cash | - | - | -1.00 | - | -1.00 | - |
| Net cash flow / Change in cash | 93.97 Thousand | -12.82 Thousand | -64.6 Thousand | -8.43 Million | 16.44 Thousand | -159.25 Thousand |
| Free Cash Flow | -1.58 Million | -2.64 Million | -4.08 Million | -10.84 Million | -6.28 Million | -465.75 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.46 Million | -1.44 Million | -2.2 Million | -8.01 Million | -2.15 Million | -1.86 Million |
| Depreciation & Amortization | 383.58 Thousand | 383.49 Thousand | 443.64 Thousand | 1.71 Million | 424.04 Thousand | 422.72 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 541.72 Thousand | 700.05 Thousand | 1.16 Million | 3.03 Million | 616.21 Thousand | 418.48 Thousand |
| Other non-cash items | 295.78 Thousand | 279.98 Thousand | 478.41 Thousand | 2.45 Million | 381.96 Thousand | 539.71 Thousand |
| Investing Cash Flow | - | -5000.00 | -17.9 Thousand | -65.32 Thousand | -22.84 Thousand | -9350.00 |
| Investments in PPE | -1.00 | -5000.00 | -17.9 Thousand | -65.32 Thousand | -22.84 Thousand | -9350.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -65.32 Thousand | -65.32 Thousand | - | - |
| Financing Cash Flow | 618.03 Thousand | 368.81 Thousand | 115.75 Thousand | 1.68 Million | 745.02 Thousand | 427.62 Thousand |
| Debt repayment | -618.03 Thousand | -368.81 Thousand | -115.75 Thousand | -1.68 Million | -40.18 Thousand | -53 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 536.85 Thousand | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | 448.64 Thousand | 115.75 Thousand | 292.94 Thousand | 785.21 Thousand | 480.62 Thousand |
| Accounts receivables | -186.57 Thousand | -6881.00 | 544.84 Thousand | 431.31 Thousand | -47.56 Thousand | 2697.00 |
| Accounts payables | 626.59 Thousand | 548.62 Thousand | 326.11 Thousand | 1.98 Million | 625.92 Thousand | 634.5 Thousand |
| Inventory | 31.37 Thousand | -49.3 Thousand | 139.98 Thousand | 297.39 Thousand | 66.41 Thousand | -262.67 Thousand |
| Other working capital | 70.33 Thousand | 207.61 Thousand | 153.58 Thousand | 318.2 Thousand | -28.56 Thousand | 43.94 Thousand |
| Cash at beginning of period | 107.64 Thousand | 100.92 Thousand | 1495.00 | 6951.00 | 8190.00 | 73.23 Thousand |
| Cash at end of period | 189.05 Thousand | 107.64 Thousand | 100.92 Thousand | 100.92 Thousand | 1495.00 | 8190.00 |
| Capital Expenditure | -1.00 | -5000.00 | -17.9 Thousand | -65.32 Thousand | -22.84 Thousand | -9350.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 81.41 Thousand | 6721.00 | 99.42 Thousand | 93.97 Thousand | -6695.00 | -65.04 Thousand |
| Free Cash Flow | -536.62 Thousand | -362.09 Thousand | -16.33 Thousand | -1.58 Million | -751.71 Thousand | -492.66 Thousand |
ENTG
ANLBF
MSLA
VRNO
KLRFM
GUJPETR